Armata Pharmaceuticals Announces Phase 2 Tailwind Study Results for Inhaled AP-PA02 in NCFB Subjects

Armata Pharmaceuticals, Inc.

Post-hoc analysis showed statistically significant reduction of P.a. CFUs at day 17 (P=0.05) and day 24 (P=0.015).
Approximately one-third of AP-PA02 monotherapy subjects achieved at least a 2-log CFU reduction versus none on placebo.
Inhaled AP-PA02 was well-tolerated with mild, self-limiting adverse events; one possibly related serious adverse event reported.
AP-PA02 is a novel multi-phage therapeutic for chronic Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis.
Results suggest AP-PA02 monotherapy may be as effective as combination with anti-pseudomonal antibiotics in reducing lung P.a. burden.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.